Pages that link to "Q37568307"

The following pages link to Emerging role of PPAR ligands in the management of diabetic nephropathy (Q37568307):

Displaying 13 items.

• Nuclear receptors in renal disease (Q35120702) (← links)
• Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy? (Q35183612) (← links)
• Identification of genes and signaling pathways associated with diabetic neuropathy using a weighted correlation network analysis: A consort study (Q37468244) (← links)
• Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? (Q37470310) (← links)
• Nuclear hormone receptors in diabetic nephropathy. (Q37737555) (← links)
• Interplay between statins and PPARs in improving cardiovascular outcomes: a double‐edged sword? (Q37905844) (← links)
• Healing the diabetic heart: Does myocardial preconditioning work? (Q37938329) (← links)
• Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? (Q37941943) (← links)
• Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes (Q38160494) (← links)
• Protective Effects of Total Glycoside From Leaves on Diabetic Nephropathy Rats via Regulating the Metabolic Profiling and Modulating the TGF-β1 and Wnt/β-Catenin Signaling Pathway (Q57113420) (← links)
• Regulatory Efficacy of Protease Hydrolyzate on Lipid Metabolism and Gut Microbiota in High-Fat Diet-Fed Rats (Q60956914) (← links)
• MicroRNA-29a Attenuates Diabetic Glomerular Injury through Modulating Cannabinoid Receptor 1 Signaling (Q61796627) (← links)
• A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-α Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy. (Q64925064) (← links)